{
    "nct_id": "NCT03517085",
    "official_title": "A Phase 1/2, Open-Label Safety and Dose-Finding Study of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Glucose-6- Phosphatase (G6Pase) in Adults With Glycogen Storage Disease Type Ia (GSDIa)",
    "inclusion_criteria": "* Males and females ≥18 years of age\n* Documented GSDIa with confirmation by molecular testing\n* Documented history of ≥1 hypoglycemic event with blood glucose <60 mg/dL (<3.33 mmol/L)\n* Patient's GSDIa disease is stable as evidenced by no hospitalization for severe hypoglycemia during the 4-week period preceding the screening visit\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Anti-AAV8 neutralizing antibody titer ≥1:5\n* Screening or Baseline (Day 0) blood glucose level <60 mg/dL (<3.33 mmol/L)\n* Liver transplant, including hepatocyte cell therapy/transplant\n* Presence of liver adenoma >5 cm in size\n* Presence of liver adenoma >3 cm and ≤5 cm in size that has a documented annual growth rate of ≥0.5 cm per year\n* Significant hepatic inflammation or cirrhosis as evidenced by imaging or any of the following laboratory abnormalities: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > upper limit of normal (ULN), total bilirubin > 1.5 x ULN, or alkaline phosphatase > 2.5 x ULN\n\nNote additional inclusion/exclusion criteria may apply, per protocol.",
    "miscellaneous_criteria": "Key"
}